Sionna Therapeutics, Inc. (NASDAQ:SION) Receives $47.63 Consensus Price Target from Analysts

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) have received a consensus rating of “Moderate Buy” from the eleven research firms that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $47.6250.

Several brokerages have recently commented on SION. Citigroup assumed coverage on shares of Sionna Therapeutics in a research report on Tuesday, February 24th. They set an “outperform” rating for the company. Royal Bank Of Canada reaffirmed an “underperform” rating and set a $24.00 price objective on shares of Sionna Therapeutics in a research note on Monday, December 1st. BTIG Research reissued a “buy” rating and issued a $58.00 target price on shares of Sionna Therapeutics in a research note on Wednesday, January 14th. Lifesci Capital upgraded Sionna Therapeutics to a “strong-buy” rating in a report on Wednesday, February 25th. Finally, Wall Street Zen raised Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th.

Insiders Place Their Bets

In other news, major shareholder Tpg Gp A, Llc sold 250,000 shares of Sionna Therapeutics stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $40.00, for a total transaction of $10,000,000.00. Following the transaction, the insider directly owned 6,494,962 shares of the company’s stock, valued at $259,798,480. This trade represents a 3.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Peter A. Thompson sold 29,063 shares of the company’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $44.58, for a total transaction of $1,295,628.54. Following the completion of the sale, the director owned 3,530,702 shares of the company’s stock, valued at approximately $157,398,695.16. This represents a 0.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 382,368 shares of company stock worth $15,898,607. Company insiders own 3.90% of the company’s stock.

Institutional Investors Weigh In On Sionna Therapeutics

A number of hedge funds have recently modified their holdings of SION. Russell Investments Group Ltd. bought a new position in Sionna Therapeutics in the third quarter valued at $30,000. BNP Paribas Financial Markets acquired a new position in shares of Sionna Therapeutics during the 2nd quarter worth about $31,000. GF Fund Management CO. LTD. bought a new position in shares of Sionna Therapeutics in the 4th quarter valued at about $36,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Sionna Therapeutics in the 2nd quarter valued at about $45,000. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Sionna Therapeutics in the fourth quarter valued at about $58,000.

Sionna Therapeutics Trading Down 3.8%

Shares of NASDAQ:SION opened at $36.54 on Wednesday. Sionna Therapeutics has a 1-year low of $7.26 and a 1-year high of $45.00. The stock has a market capitalization of $1.63 billion and a P/E ratio of -7.50. The business has a 50-day moving average price of $39.78 and a two-hundred day moving average price of $35.13.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.